相关实验视频

Updated: Jun 6, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

系统性瘤回归与协同疗法:放射治疗和CAR-T

Xingyu Ma¹, Wei Zhang¹, Miao Zeng¹

¹Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Hematology Institution of Shenzhen University, Shenzhen University Health Science Center, Shenzhen Clinical Research Center for hematologic disease, Shenzhen University, Shenzhen, China.

Cell death discovery

|November 23, 2024

概括

结合放射治疗和Claudin18.2特异性仿真抗原受体T细胞 (CAR-T) 疗法在胰腺癌中显示出有前途. 这种协同作用增强了瘤杀伤,并通过促进T细胞透和全身免疫来触发远距离瘤的回归.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
癌症研究癌症研究

背景情况:

胰腺管道腺癌 (PDAC) 在消化系统癌症中预后不佳.
克劳丁18.2特异性仿制抗原受体T细胞 (CAR-T) 疗法在PDAC中证明了最近的临床疗效.
放射治疗可以激活全身免疫力,并诱导腹膜效应,但其与PDAC的CAR-T治疗的结合并未得到充分理解.

研究的目的:

研究在PDAC治疗中将CLDN18.2CAR-T疗法与放射治疗相结合的协同效应和潜在机制.
评估这种组合治疗在PDAC的临床前小鼠模型中的疗效.

主要方法:

开发一种特定于CLDN18.2的CAR-T疗法.
治疗在单边和双边小鼠瘤模型中的应用.
分析瘤杀伤效应,免疫细胞增殖和化基因水平.

主要成果:

组合疗法在单边模型中显著改善了瘤杀伤.
在双边模型中,协同疗法诱导了局部和远部瘤的回归.
机制包括辐射诱导的亡,增强的CD8+T细胞增殖,以及增加的化学基因CCL2水平,促进T细胞透.

结论:

联合放射治疗和CLDN18.2 CAR-T疗法为治疗PDAC,包括转移性疾病提供了一个有希望的策略.
这项研究阐明了CAR-T细胞增强放射治疗效应的机制.
这种方法为打击转移性胰腺癌提供了一种新的策略.

更多相关视频

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...